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Clinical Applications of Recombinant Human Bone Morphogenetic Protein-2
for Bone Augmentation Before Dental Implant Placement
Craig Misch* and Hom-Lay Wang†
Introduction: Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-b superfamily. They
are involved in the differentiation of pluripotent mesenchymal cells, and new bone is formed through osteoblastic induction.
Therefore, BMPs are commonly implicated in bone remodeling and regeneration. Recombinant human BMP-2 with absorbable
collagen sponge (rhBMP-2/ACS) as its carrier recently received Food and Drug Administration approval for clinical use in sinus
augmentations and localized ridge preservation after extractions. This article discusses the clinical use of rhBMP-2/ACS for alve-
olar ridge repair after extraction and ridge augmentation procedures before dental implant placement.
Case Presentation: Two clinical cases that required socket and ridge augmentation, before dental implant placement,
were treated with rhBMP-2/ACS. In socket augmentation, rhBMP-2/ACS and 20% of mineralized cancellous and cortical bone
allograft were used. For ridge augmentation, guided bone regeneration using titanium mesh with fixation pins and a mixture of
rhBMP-2/ACS and mineralized bone allograft was performed. Clinical and radiographic evaluation of the treated areas after 6
months of healing showed excellent bone regeneration that facilitated subsequent implant placement. In addition, healing of
soft tissue at rhBMP-2-grafted sites appeared to be accelerated.
Conclusion: rhBMP-2 can be an agent that is used to promote socket repair as well as ridge augmentationwhen combined
with a small component of mineralized bone allograft. Clin Adv Periodontics 2011;1:118-131.
Key Words: Alveolar ridge augmentation; bone morphogenetic protein; dental implants.
Background
In the past decade, the application of recombinant
technologies has produced biomimetic devices that stimulate
tissue replacement.1 One example is recombinant human
bone morphogenetic protein-2 (rhBMP-2) on an absorbable
collagen sponge (ACS) carrier.‡ This commercially available
product stimulates host cells to differentiate into bone
forming cells.2 As such, it was recently approved by the Food
and Drug Administration (FDA) for clinical use in sinus
augmentation and localized alveolar ridge augmentations
for defects associated with extraction sockets. In this
product, the growth factor is added to an ACS carrier. This
article discusses the clinical use of rhBMP-2 for alveolar
ridge repair after extraction and ridge augmentation pro-
cedures before dental implant placement.
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Extraction Site Defects
Alveolar bone loss after tooth extraction is well docu-
mented,3,4 with significant horizontal bone resorption oc-
curring shortly after tooth removal that approached 50%
of the baseline ridge width at 12 months.5 This bone re-
modeling is unavoidable because of the loss of the bundle
bone,6 and hence, it adversely impacts the ability to prop-
erly place dental implants. This is particularly noteworthy
in the esthetic zone because studies6-9 found that the vast
majority of patients present with a thin buccal plate, which
undergoes substantial vertical and horizontal crestal bone
loss after tooth extraction,6 thus resulting in a residual
ridge that is deficient in width to house a dental implant
and also have a minimum of 1.8 to 2 mm of buccal bone
thickness needed for long-term stability of the hard- and
soft-tissue profiles around the dental implant.7-9 In addi-
tion, it was observed that more severe bone loss occurred
in clinical situations in which teeth were extracted as a re-
sult of advanced periodontal disease because the inflam-
matory disease resulted in circumferential vertical and
horizontal bone loss. Grunder et al.10 discussed ideal im-
plant positioning in the esthetic zone and pointed out that
the presence of bone determines soft-tissue contour, and
that clinicians need to focus on bone volume to achieve
ideal esthetic results. There is a generalized agreement that
socket preservation techniques are beneficial inminimizing
bone volume loss after extraction; unfortunately, there is
a lack of consensus on the ideal graft materials and tech-
niques to use.11,12
Conventional approaches to socket bone grafting for fu-
ture implant placement involve the use of various graft
materials with or without barrier membranes. When the
socket walls are intact, osteoconductive graft materials
can be used and barrier membranes may not be necessary.
However,when socketwalls aremissing, regenerative tech-
niques that have greater biologic capacity for bone forma-
tion are often used. These may include osteoinductive graft
materials with or without the use of barrier membranes.
Choices of osteoinductive graft materials include autoge-
nous bone, demineralized freeze-dried bone allograft
(DFDBA), and rhBMP-2/ACS. Autogenous bone grafts usu-
ally require a secondary donor site and are associated with
increased morbidity. DFDBA contains miniscule quantities
of BMP and is therefore only weakly osteoinductive.13,14
On the contrary, rhBMP-2 is highly osteoinductive and
has been evaluated in the socket defect application.15 Table
1 lists the benefits of using rhBMP-2 for socket augmenta-
tion. Table 2 shows research published on using rhBMP-2
for socket repair.
Case Report: Socket Repair
The patient is a 37-year-old female with a history of oral
trauma, endodontic treatments, and chronic infections as-
sociated with three maxillary anterior teeth (#7 through
#9) (Fig. 1a). The three teeth were planned for extraction
and socket augmentation. Periapical radiographs and
a cone beam computed tomography (CBCT) scan of the
maxilla were obtained preoperatively (Figs. 1b and 1c).
TheCBCTscan showed significant loss of the facial cortex
around all three anterior teeth. Before surgery, written in-
formed consent was obtained, and the patient received
a loading dose of 1 g amoxicillin, 8 mg dexamethasone,
and 10 mL of 0.12% chlorhexidine rinse. After local an-
esthesia, the incisors #7 through #9 were extracted, and
the sockets were thoroughly curetted of all soft tissue rem-
nants (Fig. 1d). The facial cortex was found to be com-
pletely absent to the apical regions of the sockets. A
bone graft kit,x which had a 1  2-inch ACS and 1.4 cc
rhBMP-2 (1.5 mg/mL),k was used for the defect repair.
The ACS was evenly saturated with rhBMP-2, and 15
minutes were allowed for the binding of rhBMP-2 to
ACS before it was cut into smaller pieces and mixed with
a small quantity (20%by volume) of mineralized cortical/
cancellous bone allograft.{ The graft mixture was placed
into the extraction sockets planned for implant placement
(#7 and #9) and gently compressed to fill the socket level
with the palatal bonemargins (Figs. 1e and 1f). The center
socket (#8) planned for the implant bridge pontic was
filled with a relatively non-resorbable bovine hydroxyap-
atite# so that the bone width could be indefinitely main-
tained. A piece of the rhBMP-2/ACS alone (no bone
allograft) was then placed over the sockets to the level
of the surrounding gingiva. The collagen sponges were se-
cured using 4-0 chromic gut interrupted sutures in a cross
pattern over the sockets. A fixed resin bridge (#6 through
#10) was fabricated as a provisional restoration during
healing, and acrylic was added to create ovate pontics
(Fig. 1g). Periapical radiographs were obtained of the
grafted site. The patient was placed on a postsurgical reg-
imen that consisted of a tapering dose of dexamethasone
for 2 days (4.5 to 1.5 mg), antibiotic therapy (amoxicillin
at 500 mg three times per day for 7 days), 0.12% chlor-
hexidine rinse twice per day for 2 weeks, and a narcotic
analgesic when necessary. At the 2-week postsurgery eval-
uation, the patient experienced moderate swelling of the
upper lip and face but healed without complications. The
grafted site was allowed to heal for 5 months. A CBCT
TABLE 1 Benefits of Using rhBMP-2 for Socket Augmentation
Promotes soft-tissue healing
Requires no primary wound closure
Minimizes surgery time
Reduces potential postsurgical infection
Accelerates cell migration
Promotes early bone formation
x XS INFUSE Bone Graft kit, Medtronic.
k INFUSE Bone Graft, Medtronic.
{ MinerOss, BioHorizons, Birmingham, AL.
# Bio-Oss, Osteohealth, Shirley, NY.
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scan was obtained before implant surgery to evaluate the
graft healing and select the appropriate size implants (Fig.
1h). The CBCT scan found favorable regeneration of the
alveolar bone and adequate bone volume for implant
placement. Clinically, the surgical site presented with ad-
equate hard- and soft-tissue dimensions (Fig. 1i). Under
local anesthesia, an incision was made along the ridge
crest, and a full thickness mucoperiosteal flap was ele-
vated to expose the residual ridge. Favorable bone fill
and regeneration of the facial bone was observed. The im-
plant osteotomies were prepared according to the drilling
sequence of the manufacturer, and the bone density was
found to be type 3.16 Two dental implants** were placed
in a two-stage surgical approach (Figs. 1j through 1l), and
a 4-month healing periodwas allowed before the implants
were uncovered and restored.
Ridge Augmentation
Several procedures, such as onlay bone grafting, ridge split-
ting, guided bone regeneration (GBR), and distraction





























































































































Key words used in the PubMed literature search were: rhBMP-2, socket, and extraction socket augmentation. PLGA/GS ¼ polylactic acid and polyglycolic acid
copolymer-coated gelatin sponge; RCT ¼ randomized clinical trial.
** Osseospeed TX, Astra Tech, Mölndal, Sweden.
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FIGURE 1 Case 1. 1a Preoperative view of failing maxillary anterior teeth (#7 through #9). The patient had chronic fistulas over the apical mucosa. 1b A
periapical radiograph of the failed maxillary incisors. 1c A cross-sectional view of a maxillary CT scan revealed no facial bone over the roots. 1d The maxillary
extraction sockets with a lack of a facial cortex. 1e The rhBMP-2/ACS mixed with bone substitute was placed into the sockets. 1f The graft mixture was
packed level with the palatal bone margins. 1g A provisional bridge was used as temporary tooth replacement during healing. 1h A cross-sectional view of a CT
scan after 5 months of graft healing. 1i A preoperative view before implant surgery. 1j Placement of two implants (Osseospeed TX, Astra Tech) in the reconstructed
maxilla. 1k An occlusal view of the left lateral incisor implant. Note the regeneration of the facial cortex. 1l An occlusal view of the right central incisor implant. Note
the regeneration of the facial cortex.
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osteogenesis, are available to augment an atrophic residual
ridge for implant placement. When significant defects are
encountered, autogenous bone graft is often used alone or
in combination with other bone substitutes to regenerate
larger volumes of bone. The biologic properties of au-
togenous bone, including properties of osteogenesis, os-
teoinduction, and osteoconduction, are advantageous in
the reconstruction of a severely atrophic ridge. Currently,
investigations to determine the feasibility of replacing au-
togenous bone graft in ridge augmentation with rhBMP-2/
ACS are being conducted. Therefore, the use of rhBMP-2/
ACS for residual ridge augmentation in this case report is
considered an off-label application by the FDA.
Case Report: Ridge Augmentation
The patient is a 42-year-old male with mandibular left par-
tial edentulism and a severe vertical defect. ACBCTscan of
the mandible was obtained preoperatively (Fig. 2a). There
was z4.0 mm of bone superior to the mandibular canal.
The original plan was to harvest autogenous bone for
the reconstruction of the defect. As an alternative, the
use of rhBMP-2 was proposed, and written informed con-
sent for use of the product in an off-label manner was ob-
tained.Thepatient received a loading dose of 1 g amoxicillin,
8 mg dexamethasone, and 10 mL of 0.12% chlorhexidine
rinse. Local anesthesia was obtained using a mandibular
nerve block with 0.25% bupivacaine, 1:200,000 epineph-
rine, and buccal infiltration with 2% lidocaine, 1:100,000
epinephrine. The rhBMP-2/ACS was prepared just before
surgery to allow adequate time for protein binding. A
bone graft kit†† was used. A 1  2-inch collagen sponge
was evenly saturated with the reconstituted rhBMP-2
(1.5 mg/mL) for 15 minutes. It was subsequently cut into
smaller pieces and mixed with a small quantity (20% by
volume) of mineralized bone allograft.‡‡
An incisionwasmade along the ridge crest through kerati-
nized gingiva in the posterior mandible. A lateral releasing
incision was made at the base of the retromolar pad. A short
anterior releasing incision was made mesial to the most pos-
terior tooth bordering the defect. A mucoperiosteal flap was
reflected to completely expose the atrophic ridge (Fig. 2b).
The lingual reflection extended to the mylohyoid ridge.
The future implant sites were planned, and the size of the
mesh needed for graft coverage was assessed. The 0.2-
mm-thick titanium mesh was trimmed to extend well poste-
rior to the distal implant site. The lateral borders of themesh
extended slightly beyond the desired area of augmentation to
FIGURE 2 Case 2. 2a A preoperative radiograph of the left posterior mandible revealed a vertical bone defect. 2b A mucoperiosteal flap was reflected to expose
the defect. 2c The cortex over the defect site was perforated to allow access to the intramedullary stem cells. 2d The titaniummesh was contoured over the defect
and filled with the mixture of rhBMP-2/ACS and mineralized bone allograft. 2e The titanium mesh was fixated with monocortical screws. 2f Tension-free primary
closure of the flaps over the graft site. 2g A cross-sectional view of the CT scan of the mandible revealed the regenerated bone under the titanium mesh. 2h A
cross-sectional view of the CT scan after implant placement. 2i Exposure of the implants for placement of healing abutments after 2 months of healing.
†† XS INFUSE Bone Graft kit, Medtronic.
‡‡ MinerOss, BioHorizons.
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4.4 – 0.4 mm;
test group 2:
4.2 – 0.7 mm;
test group 3:
4.2 – 1.2 mm
versus
control group:
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contact the residual ridge. The mesh was molded into a U-
shape and fitted onto the atrophicmandiblewith a periosteal
elevator. The cortex of the mandibular crest was generously
perforated to produce bleeding in multiple sites with a #6
round carbide bur. The pilot holes for the fixation screws
were alsoprepared at this time (Fig. 2c). The concave portion
of the mesh was packed with the rhBMP-2/ACS and allo-
graft mixture (Fig. 2d), reinserted over the mandible, and
compressed into place. Two monocortical fixation screws
(1.5  4.0 mm) were placed along the buccal cortex
(Fig. 2e). A #12 scalpel blade was used to incise the peri-
osteum along the base of the flap to obtain flap release.
Placing a gloved finger along the mylohyoid ridge and
stretching the thin periosteum and soft tissue was per-
formed to achieve lingual flap release. The flap margins
were then advanced over the mesh and closed primarily
with 4-0 polyglactinxx interrupted and horizontal mat-
tress sutures (Fig. 2f). The patient continued 1 week of
antibiotic therapy, a twice daily 0.12% chlorhexidine
rinse, and was prescribed a narcotic analgesic. A tapering
dose of dexamethasone (4 to 1.5 mg) was prescribed for
2 days.
The patient experienced moderate swelling of the lower
face but otherwise healed uneventfully. The grafted site
was allowed to heal for 6 months. A CBCT scan was ob-
tained before implant surgery to evaluate the graft healing
and select appropriately sized implants (Fig. 2g). The com-
puted tomography (CT) scans revealed favorable bone fill
under the mesh, but the density appeared less than the na-
tive mandible. Under local anesthesia, an incision was
made along the ridge crest. A mucoperiosteal flap was ele-
vated to expose the mesh and fixations screws. The screws
were removed, and the edge of themesh was freed and held
with a hemostat to facilitate the dissection from the soft tis-
sue. The fibrous tissue that typically encapsulated themesh
was reflected from the bone. The implant osteotomies
were prepared according to the drilling sequence of the
manufacturer. The bone density was type 3.16 Two 4.0 
8.0 mm dental implantskk were inserted for submerged
healing (Fig. 2h). After a 2-month healing period, the sub-
merged implants were uncovered for prosthetic restoration
(Fig. 2i). Periapical radiographs were taken to evaluate the
implant healing. The implants were restored with indepen-
dent cement retained crowns.
Discussion
Although BMPs are involved in bone development, they
are pleiotropic growth factors that play a role in the growth
and differentiation of various organs. BMPs have been
found to be chemotactic for endothelial cells and can also
stimulate angiogenesis through the production of vascular
endothelial growth factor A by osteoblasts.17,18
Previous reports on the use of rhBMP-2 for alveolar bone
repair primarily focused on product safety and technical
feasibility. Howell et al.19 evaluated rhBMP-2/ACS for lo-
cal ridge preservation and augmentation. Clinical results
with 0.43 mg/mL rhBMP-2/ACS showed bone fill in the
treated extraction sites. Cochran et al.20 studied the use
of 0.43 mg/mL rhBMP-2/ACS in extraction sockets and
sites requiring ridge augmentation for future dental im-
plant placement. Implants were successfully placed and re-
stored in 10 patients and were followed for 3 years. No





























Key words used in the PubMed literature search were: rhBMP-2, vertical bone augmentation, and vertical ridge augmentation. PTFE ¼ polytetrafluoroethylene; ePTFE ¼
expanded polytetrafluoroethylene; BIC ¼ bone-to-implant contact; HA ¼ hydroxyapatite; ng/rhBMP-2 ¼ non-glycosylated recombinant human bone morphogenetic
protein-2; Ti ¼ titanium; aBSM ¼ calcium phosphate cement carrier; PLGA/GS ¼ polylactic acid and polyglycolic acid copolymer-coated gelatin sponge; NSSD ¼ no
statistically significant difference.
* Nobel Biocare, Zurich, Switzerland.
† Bio-Oss, Osteohealth.
‡ Puros, Zimmer Dental, Carlsbad, CA.
x Bio-Oss, Osteohealth.
jj Puros, Zimmer Dental.
{ Bio-Oss, Osteohealth.
# Puros, Zimmer Dental.
** Bio-Oss, Osteohealth.
†† Puros, Zimmer Dental.
‡‡ Bio-Oss, Osteohealth.
xx Puros, Zimmer Dental.
xx VICRYL, Ethicon, Johnson & Johnson, Somerville, NJ.
kk Osseospeed TX, Astra Tech.
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adverse events were reported, and the implants had stable
marginal bone levels and healthy peri-implant tissues.
Fiorellini et al.15 performed a randomized multicenter
study evaluating two concentrations of rhBMP-2 (0.75
and 1.5 mg/mL) in the repair of extraction socket buccal
wall defects for dental implant placement. The sockets
were filled with rhBMP-2/ACS, and primary closure over
the grafted sites was obtained. At 4 months, patients
treated with the higher concentration of rhBMP-2 had sig-
nificantly greater bone augmentation and adequate bone
volume for implant placement.
In a recent case series, the use of rhBMP-2/ACS was
evaluated for the repair of significant bone defects after
removal of maxillary central incisors.21 The extraction
sockets all had >50% buccal bone loss. The sockets were
grafted with rhBMP-2/ACS and a small amount of bone
substitute. The surgical technique was modified, because
primary closure was not obtained over the grafted sockets.
Dental implants were inserted after 4 to 6 months of heal-
ing, and CBCT scans were used to evaluate the alveolar
repair. Dental implants were placed in all grafted sites
without the need for additional bone augmentation. A
comparison of preoperative and postgraft CBCT scans
found a slight loss in alveolar width at the crest of 1.07
mm (range, þ0.63 to –2.18 mm). Although primary clo-
sure was not achieved over the graft, the healing or induc-
tion of bone growth was not compromised. The bone
quality of the regenerated tissue was primarily type 3,16
with all 10 implants well osseointegrated and restoredwith
single crowns.
In this case series,21 no flap was elevated and no attempt
was made to close the soft tissue over the grafted socket.
TheACS used as a carrier for the rhBMP-2 allowed connec-
tive tissue in-growth and epithelialization over the grafted
site. The healing of soft tissue over rhBMP-2-grafted sites
appeared to be accelerated as shown in the repair of open
tibial fractures with rhBMP-2.22 This might be attributable
to an increase in vascular supply because BMPs can stim-
ulate angiogenesis through the production of vascular en-
dothelial growth factor A by osteoblasts.17,18
In a study by Fiorellini et al.,15 radiographic measure-
ments were taken of cross-sectional CT scan images after
extraction and socket grafting. These measurements were
repeated 4 months after the socket grafts had healed. An
average bone width gain of 3.53 mm at the crest was
found in the patients treated with 1.5 mg/mL rhBMP-2.
Misch21 found a slight loss in overall alveolar crestal bone
width in 9 of 10 cases with an average loss of 1.07 mm.
The disparity in treatment outcomes could be attributed
to differences in measurement site selection because
Misch took the preoperative width measurements from
the palatal bone at the ridge crest to the facial aspect of
the root because the facial cortex was absent in most
cases.
In the study by Fiorellini et al.,15 three of 18 (14%) of the
1.5 mg/mL rhBMP-2/ACS grafted sockets required a sec-
ondary bone augmentation at implant placement. Compar-
atively, in the case series presented by Misch in 2010,21
a small amount of mineralized bone allograft (20%) was
mixed with the rhBMP-2/ACS and no additional bone re-
pair was needed at implant placement, thus suggesting
that ACS used as a carrier for the BMPmolecule has rather
poor scaffolding qualities to resist flap compression under
pressure and the inclusion of a bulking agent or matrix
would provide additional three-dimensional support to
the graft.23
The traditionalmethods to repair large extraction socket
defects include bone substitutes with barrier membranes
or block bone grafting. The use of a barrier membrane of-
ten necessitates flap elevation and advancement to obtain
primary closure. Exposure of expanded polytetrafluoro-
ethylenemembranes can result in infection and a reduction
in bone regeneration.24 Exposed collagenmembranes, con-
versely, lose their structural integrity and resorb rapidly.25
Block grafting is usually performed as a delayed procedure
after soft-tissue healing over the socket to prevent graft ex-
posure and also to minimize the alteration of the gingival
anatomy. Performing an immediate bone repair and not
having to obtain primary soft-tissue closure over the
rhBMP-2/ACS grafted socket offers significant benefits.
There is a reduction in the amount of soft-tissue manipula-
tion because no flap is elevated or advanced. This shortens
the surgical time and can reduce postoperative pain. It also
maintains the normal gingival architecture and facial posi-
tion of the keratinized tissue.
Fiorellini et al.15 measured the bone density of healed
sockets using CT scans, and a comparison of the new bone
formed at 4 months revealed no significant difference in
density among the groups (no treatment, ACS alone, and
rhBMP-2/ACS). Histologic samples showed remodeling
of immaturewoven bone into lamellar bone.No comments
were made regarding the bone quality noted during im-
plant site preparation and placement. In a sinus bone graft
study by Boyne et al.,26 the rhBMP-2-grafted sites had sig-
nificantly less radiographic bone density than autograft
filled sites at 4 months after surgery. This difference was
likely attributable to variation in the mechanism of
bone formation because the de novo bone induction by
rhBMP-2 required more time for mineralization. Implants
were subsequently inserted after a mean healing period of
6.9 –1months, and the investigators rated the clinical bone
quality similar between the autograft and 1.5 mg/mL
rhBMP-2 group. This finding was consistent with the bone
quality noted in the cases treated. At 4 months of healing,
the presence of woven bone providedminimal resistance to
drilling. The use of osteotomes and undersizing of the os-
teotomy could help attain implant stability in softer bone
sites. Allowing the rhBMP-2-grafted sockets to heal an ad-
ditional 1 or 2 months appeared to result in an improve-
ment in bone quality. A longer healing period of ‡6
months appeared to be beneficial when using rhBMP-2
for onlay augmentation. It was unclear whether the addi-
tion of a mineralized bone substitute would influence the
quality of regenerated bone. It appeared that the resorption
of bone substitutes was accelerated by the cellular cascade
induced by rhBMP-2.27
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Although the ACS has been found to be an optimal
carrier for the rhBMP-2 molecule, it has poor scaff-
olding properties to resist flap compression when used
for onlay ridge augmentation. Titanium mesh has been
proposed as a method to provide support and protection
of the rhBMP-2/ACS during healing. Titanium mesh can
be used with onlay bone augmentation to protect the col-
lagen carrier and maintain the space for bone in-growth.
Herford and Boyne28 successfully used titanium mesh to
maintain the periosteal envelope around large mandibular
continuity defects treated with rhBMP-2/ACS. The mesh
thickness of 0.2 mm would adequately resist flexing and
micromovement during healing and yet be thin enough
to mold. The use of titanium mesh for bone augmentation
should not be confused with GBR techniques. GBR uses
a cellular occlusive barrier membrane to impede soft-tis-
sue penetration and allow the slower growing bone cells
to repopulate the osseous defect.29 Titanium mesh acts
as a protectivematrix tomaintain space and facilitate bone
in-growth but is not cell occlusive. Combining rhBMP-2/
ACS with a barrier membrane does not seem to provide
any additional value andmay actually be biologically coun-
terproductive because it occludes cells that may contribute
to the bone-forming process and impedes vascularity from
the soft-tissue flap.30-32
The existing human trials on rhBMP-2/ACS for bone
augmentation have not relied on GBR for bone forma-
tion.15,26 The inclusion of a bulking agent or matrix has
also been suggested to provide additional three-dimen-
sional support for the collagen sponge.33 However, the ad-
dition of a bone substitute must be weighed against the
reduction of the amount of BMP that will be present in
the grafted site. A small amount of particulate bone substi-
tute (20%)may provide additional scaffold without signif-
icantly diluting the effects of rhBMP-2.27
Being a locally acting growth factor, rhBMP-2 induces
bone formation at the site of application. It is chemotactic
for mesenchymal stem cells, osteoprogenitor cells, and os-
teoblasts. Preparation of the osseous recipient site is there-
fore important, because these cells are found in bone
marrow and to a lesser degree in soft tissue. The cortex
of the recipient site should be generously perforated inmul-
tiple sites with a bur to allow access to themarrow. Primary
tension-free closure of the soft tissue flaps over the grafted
site is necessary to prevent wound dehiscence and early
exposure of the mesh. Generally, a ‘‘PASS’’ (for primary
wound closure, angiogenesis, space creation, and mainte-
nance and wound stability) principle should be followed.34
Table 3 is a summary of research on the use of rhBMP-2 for
vertical bone augmentation.
Ridge augmentation using rhBMP-2/ACS with titanium
mesh offers another approach in the management of the
atrophic residual ridge. From a patient’s perspective, there
are significant benefits because no autogenous bone graft is
harvested and thus there is no morbidity associated. The
technical procedure is relatively straightforward and as
such requires minimal surgical time. However, the ability
to manage the surgical flaps to attain tension-free primary
closure is still essential. The disadvantages of this technique
compared to the use of an autograft include longer graft
healing times, softer bone quality, and higher material
costs. Although preliminary results appear promising,
there are questions regarding the long-term stability of
the onlay grafted bone under loading. Additional studies
will be helpful in determining specific indications and lim-
itations of this technique.
Conclusions
The use of growth factors offers a new approach to the re-
pair of alveolar defects in preparation for implant place-
ment. The case reports in this article demonstrate the use
of rhBMP-2 in the repair of large extraction socket defects
and localized ridge augmentation. The collagen sponge car-
rier appears to have space making limitations that may re-
quire addition of a matrix, such as a bone substitute, or use
of a scaffold, such as titaniummesh, for graft protection in
these applications. The repair of a large alveolar defect as-
sociated with a failed tooth may be performed at the time
of extraction using rhBMP-2/ACS. This approach does not
require the use of a barrier membrane and/or flap manip-
ulation and advancement. Ridge augmentation using
rhBMP-2/ACS with titanium mesh offers an alternative
method to reconstruct the atrophic residual ridge. The
benefits of this technique include relative technical ease
and the elimination of autogenous bone harvest with asso-
ciatedmorbidity. The disadvantages include long graft heal-
ing times, softer bone quality, and higher material costs. n
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Summary
Why is this case new information? n This case uses rhBMP/ACS mixed with human allograft for socket
repair
n This case uses rhBMP/ACS mixed with human allograft and
supported with titanium mesh for horizontal and vertical bone
augmentation
What are the keys to successful
management of this case?
n rhBMP-2 was used to accelerate soft tissue healing, minimize healing
time and potential postsurgical infection, and promote cell migration
and early bone formation
n Human allograft and titanium mesh were used to create and maintain
the space that is needed for bone to grow
n The `̀ PASS'' (primary wound coverage, angiogensis, space, and
stability) principle was followed
What are the primary limitations to n Lack of primary wound closure attributable to flap tension
success in this case? n Lack of angiogenesis
n Lack of space creation and maintenance
n Lack of wound and implant stability
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36. Wikesjö UM, Sorensen RG, Kinoshita A, Wozney JM. RhBMP-2/
alphaBSM induces significant vertical alveolar ridge augmentation and
dental implant osseointegration. Clin Implant Dent Relat Res 2002;4:
174-182.
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